Autologous Cord Blood Cell Therapy for Neonatal Encephalopathy

Inclusion Criteria: Infants are eligible if they meet all the following inclusion criteria except 4. 1. ≥36 weeks gestation 2. Either a 10-minute Apgar score ≤5, continued need for resuscitation for at least 10 minutes, or severe acidosis, defined as pH \<7.0 or base deficit ≥16 mmol/L in a sample of umbilical cord blood or any blood during the first hour after birth 3. Moderate to severe encephalopathy (Sarnat II to III) 4. A moderately or severely abnormal background amplitude-integrated EEG (aEEG) voltage, or seizures identified by aEEG, if monitored 5. Up to 24 hours of age 6. Autologous umbilical cord blood available to infuse within 3 days after birth 7. A person with parental authority must have consented for the study. Exclusion Criteria: 1. Known major congenital anomalies, such as chromosomal anomalies, heart diseases 2. Major intracranial hemorrhage identified by brain ultrasonography or computed tomography 3. Severe growth restriction, with birth-weight less than 1800 g 4. Severe infectious disease, such as sepsis 5. Hyperkalemia 6. Outborn infants (Infants born at hospitals other than the study sites) 7. Volume of collected cord blood \<40 ml 8. Infants judged critically ill and unlikely to benefit from neonatal intensive care by the attending neonatologist